Attachment 2 - claims analysis results

CMS-10675_Attachment_2_Results_from_Claims_Analysis_051818_508.docx

Evaluation of the CMS Quality Improvement Organizations: Medication Safety and Adverse Drug Event Prevention (CMS-10675)

Attachment 2 - claims analysis results

OMB: 0938-1356

Document [docx]
Download: docx | pdf

CMS-10675 Attachment 2

Readmission Rates for Medicare Beneficiaries Using High-Risk Medications (HRM) by Provider’s Participation in the QIN-QIO Program to Prevent Adverse Drug Events: Results from Preliminary Analysis of Medicare Claims (QIN-QIO Implementation Begins January 2015)

Figure 1. All-Cause Readmissions, HRM Beneficiaries*

Figure 2. Readmissions Related to Anticoagulants per 1,000 HRM Beneficiaries

Figure 3. Readmissions Related to Diabetes Agents per 1,000 HRM Beneficiaries

Figure 4. Readmissions Related to Opioids per 1,000 HRM Beneficiaries



* Readmissions due to any cause were reduced more for beneficiaries exposed to the QIN-QIO program compared to beneficiaries in the Non-QIN-QIO group by about 8% (OR = 0.92 [95% CI, 0.88-0.96] p <.0001). No statistically significant differences between groups were observed for readmission rates due to specific drug classes.

File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
File TitleAttachment 2: Readmission Rates for Medicare Beneficiaries Using High-Risk Medications (HRM) by Provider’s Participation in the
SubjectAnnual survey of quality improvement activities in CMS nursing homes both participating in and not participating in the QIN-QIO
AuthorBooz Allen Hamilton
File Modified0000-00-00
File Created2021-01-20

© 2024 OMB.report | Privacy Policy